Korea Toujeo OK Sets Stage for Tresiba Clash
This article was originally published in Scrip
Executive Summary
Sanofi's next-generation basal insulin Toujeo has been approved in South Korea and looks set to compete with Novo Nordisk's Tresiba (degludec), which is also expected to be launched there soon.